Our anti-human GAPDH in brain cancer study

Understanding the role of CD97 in brain cancer.

Sept 2023 (Department of Neurosurgery, University of Miami Hospital, University of Miami, Coral Gables, USA).

CD97 is a protein highly expressed in glioblastoma (GBM). It consists of two noncovalently bound domains: the N-terminal fragment (NTF) and the C-terminal fragment (coupling to GPCRs).

In this study, researchers investigated the effects of changing CD97 levels and its function on primary patient-derived GBM stem cells in vitro and in vivo.

High levels of CD97 correlate with metastasis suggesting that decreasing its expression may reduce cell motility and invasion. Accordingly, results show that with lower CD97 levels in cancer cells, tumors grew less, and with higher CD97 levels, tumors grew bigger.

However, it seems that is the balance between the N-terminal and C-terminal that controls whether cells stick together or spread and grow in brain cancer: the N-terminal fragment (NTF) part of CD97 stops individual cells from spreading, but when it separates from the C-terminal fragment (GPCR), it helps cells get into the brain and may make tumors grow faster.

Our anti-human GAPDH (HPA061280) polyclonal antibody was used in the study to detect all the transplanted xenografts.

Read the full article:

Slepak TI, et al. Dual role of the adhesion G-protein coupled receptor ADRGE5/CD97 in glioblastoma invasion and proliferation. J Biol Chem. 2023 Jul 28;299(9):105105.


🌎 Our antibodies are used worldwide 🌎 

Here are some latest publications.